DK2817053T3 - NATIONAL SUBMISSION DEVICES - Google Patents
NATIONAL SUBMISSION DEVICES Download PDFInfo
- Publication number
- DK2817053T3 DK2817053T3 DK13711301.5T DK13711301T DK2817053T3 DK 2817053 T3 DK2817053 T3 DK 2817053T3 DK 13711301 T DK13711301 T DK 13711301T DK 2817053 T3 DK2817053 T3 DK 2817053T3
- Authority
- DK
- Denmark
- Prior art keywords
- nasal
- housing
- subject
- delivery device
- individual
- Prior art date
Links
- 238000012384 transportation and delivery Methods 0.000 claims abstract description 42
- 239000000126 substance Substances 0.000 claims abstract description 21
- 210000003928 nasal cavity Anatomy 0.000 claims abstract description 16
- 230000003213 activating effect Effects 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 210000001331 nose Anatomy 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 16
- 238000000034 method Methods 0.000 description 6
- 210000002850 nasal mucosa Anatomy 0.000 description 6
- 206010028735 Nasal congestion Diseases 0.000 description 5
- 210000000214 mouth Anatomy 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 230000000172 allergic effect Effects 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 239000000850 decongestant Substances 0.000 description 3
- 229940124581 decongestants Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000001989 nasopharynx Anatomy 0.000 description 3
- 210000003695 paranasal sinus Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 206010033078 Otitis media Diseases 0.000 description 2
- 210000002534 adenoid Anatomy 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- -1 for example Substances 0.000 description 2
- 230000001969 hypertrophic effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000000492 nasalseptum Anatomy 0.000 description 2
- 208000005923 otitis media with effusion Diseases 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 208000024036 serous otitis media Diseases 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- 206010021518 Impaired gastric emptying Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- 208000000592 Nasal Polyps Diseases 0.000 description 1
- 206010028741 Nasal inflammation Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 102400000050 Oxytocin Human genes 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000028347 Sinus disease Diseases 0.000 description 1
- 206010041235 Snoring Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002460 anti-migrenic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 210000005225 erectile tissue Anatomy 0.000 description 1
- 210000002388 eustachian tube Anatomy 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000001288 gastroparesis Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000420 mucociliary effect Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000010352 nasal breathing Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000009745 pathological pathway Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000008786 sensory perception of smell Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000001584 soft palate Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001944 turbinate Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/08—Inhaling devices inserted into the nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0021—Mouthpieces therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
- A61M2205/586—Ergonomic details therefor, e.g. specific ergonomics for left or right-handed users
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/06—Head
- A61M2210/0618—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/06—Head
- A61M2210/0625—Mouth
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Otolaryngology (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medicinal Preparation (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261603089P | 2012-02-24 | 2012-02-24 | |
| PCT/EP2013/053748 WO2013124493A1 (en) | 2012-02-24 | 2013-02-25 | Nasal delivery devices |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2817053T3 true DK2817053T3 (en) | 2018-08-13 |
Family
ID=47915159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13711301.5T DK2817053T3 (en) | 2012-02-24 | 2013-02-25 | NATIONAL SUBMISSION DEVICES |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10179216B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2817053B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6382723B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN104428024B (cg-RX-API-DMAC7.html) |
| CA (1) | CA2865355C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2817053T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2683865T3 (cg-RX-API-DMAC7.html) |
| IN (1) | IN2014DN07610A (cg-RX-API-DMAC7.html) |
| MX (1) | MX358062B (cg-RX-API-DMAC7.html) |
| PL (1) | PL2817053T3 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2644293C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013124493A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0215270D0 (en) | 2002-07-02 | 2002-08-14 | Optinose As | Nasal devices |
| GB0311570D0 (en) | 2003-05-20 | 2003-06-25 | Optinose As | Delivery device and method |
| GB0319119D0 (en) | 2003-08-14 | 2003-09-17 | Optinose As | Delivery devices |
| GB0320171D0 (en) | 2003-08-28 | 2003-10-01 | Optinose As | Delivery devices |
| GB0420513D0 (en) | 2004-09-15 | 2004-10-20 | Optinose As | Powder delivery devices |
| GB0503738D0 (en) | 2005-02-23 | 2005-03-30 | Optinose As | Powder delivery devices |
| AU2006335994A1 (en) | 2006-01-19 | 2007-07-26 | Optinose As | Nasal administration |
| GB0602980D0 (en) | 2006-02-14 | 2006-03-29 | Optinose As | Delivery device and method |
| GB0604444D0 (en) | 2006-03-06 | 2006-04-12 | Optinose As | Nasal devices |
| GB0605799D0 (en) | 2006-03-23 | 2006-05-03 | Optinose As | Nasal delivery devices |
| GB2438834A (en) | 2006-06-08 | 2007-12-12 | Optinose As | Intranasal protein administration |
| GB2440316A (en) | 2006-07-25 | 2008-01-30 | Optinose As | Nasal inhaler with scrubber |
| GB0623731D0 (en) | 2006-11-28 | 2007-01-10 | Optinose As | Delivery device |
| GB0623728D0 (en) | 2006-11-28 | 2007-01-10 | Optinose As | Delivery devices |
| GB0623732D0 (en) | 2006-11-28 | 2007-01-10 | Optinose As | Powder delivery devices |
| GB2448193A (en) | 2007-04-05 | 2008-10-08 | Optinose As | Nasal delivery device |
| GB2448183A (en) | 2007-04-05 | 2008-10-08 | Optinose As | Nasal powder delivery device |
| GB0719299D0 (en) | 2007-10-03 | 2007-11-14 | Optinose As | Nasal delivery devices |
| GB201015371D0 (en) | 2010-09-14 | 2010-10-27 | Optinose As | Nasal delivery |
| US9949923B2 (en) | 2011-03-15 | 2018-04-24 | Optinose As | Nasal delivery |
| IN2014DN07610A (cg-RX-API-DMAC7.html) | 2012-02-24 | 2015-05-15 | Optinose As | |
| CA2865353C (en) | 2012-02-24 | 2021-07-13 | Optinose As | Nasal delivery devices |
| EP3281664B2 (en) | 2012-02-24 | 2025-10-22 | Optinose, Inc. | Nasal delivery devices |
| US11554229B2 (en) | 2013-03-26 | 2023-01-17 | OptiNose Inc. | Nasal administration |
| USD761951S1 (en) | 2013-05-23 | 2016-07-19 | Optinose As | Nosepiece unit |
| EP2868334B1 (de) | 2013-11-05 | 2017-01-11 | Benedict Gerber | Nasendusche |
| US10940277B2 (en) | 2014-11-19 | 2021-03-09 | Optinose As | Intranasal administration |
| IL294485A (en) | 2020-01-22 | 2022-09-01 | Seelos Therapeutics Inc | Reduction of side effects of nmda antagonists |
| KR20220151265A (ko) | 2021-05-06 | 2022-11-15 | 김대황 | 비강 약물 투여 장치 및 방법 |
| US20240261236A1 (en) | 2021-05-14 | 2024-08-08 | Seelos Therapeutics, Inc. | Methods of using nmda receptor antagonists |
| US20230285278A1 (en) * | 2022-03-06 | 2023-09-14 | Optinose, Inc. | Methods for treating chronic rhinosinusitis |
| CN114602046A (zh) * | 2022-05-10 | 2022-06-10 | 纳索菲德(上海)制药技术有限公司 | 向鼻腔嗅区递送药液的装置及其使用方法 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US605436A (en) | 1898-06-07 | Inhaler | ||
| US642748A (en) | 1899-02-23 | 1900-02-06 | Arthur Manners | Inhaler. |
| US746749A (en) | 1903-03-18 | 1903-12-15 | George E Seidel | Nasal medicator. |
| EP0805696B1 (en) | 1995-01-23 | 2000-03-15 | Direct-Haler A/S | An inhaler |
| US5797392C1 (en) | 1996-01-22 | 2001-01-09 | Direct Haler As | Inhaler |
| PL189855B1 (pl) | 1997-05-27 | 2005-09-30 | Direct Haler As | Urządzenie do podawania sproszkowanej substancji aktywnej |
| GB0121568D0 (en) | 2001-09-06 | 2001-10-24 | Optinose As | Nasal delivery device |
| BR0008650B1 (pt) | 1999-03-03 | 2010-12-28 | dispositivo de transmissão via nasal. | |
| GB0114272D0 (en) | 2001-06-12 | 2001-08-01 | Optinose As | Nasal delivery device |
| US6644305B2 (en) * | 2000-04-14 | 2003-11-11 | Trudell Medical International | Nasal inhaler |
| GB0015309D0 (en) | 2000-06-21 | 2000-08-16 | Djupesland Per G | Apparatus |
| ZA200306564B (en) | 2001-02-26 | 2004-10-15 | Optinose As | Nasal devices. |
| GB0207422D0 (en) | 2002-03-28 | 2002-05-08 | Optinose As | Nasal devices |
| GB0207817D0 (en) | 2002-04-04 | 2002-05-15 | Optinose As | Nasal devices |
| GB0209494D0 (en) | 2002-04-25 | 2002-06-05 | Optinose As | Nasal devices |
| GB0215270D0 (en) | 2002-07-02 | 2002-08-14 | Optinose As | Nasal devices |
| GB0215904D0 (en) | 2002-07-09 | 2002-08-21 | Team Holdings Uk Ltd | Drug delivery system and method |
| GB0300008D0 (en) | 2003-01-02 | 2003-02-05 | Optinose As | Delivery devices |
| GB0311570D0 (en) | 2003-05-20 | 2003-06-25 | Optinose As | Delivery device and method |
| GB0319119D0 (en) | 2003-08-14 | 2003-09-17 | Optinose As | Delivery devices |
| GB0320171D0 (en) | 2003-08-28 | 2003-10-01 | Optinose As | Delivery devices |
| USD530815S1 (en) | 2004-03-19 | 2006-10-24 | Optinose As | Nasal delivery device |
| GB0420513D0 (en) | 2004-09-15 | 2004-10-20 | Optinose As | Powder delivery devices |
| GB0503738D0 (en) | 2005-02-23 | 2005-03-30 | Optinose As | Powder delivery devices |
| AU2006335994A1 (en) | 2006-01-19 | 2007-07-26 | Optinose As | Nasal administration |
| EP1988953B1 (en) | 2006-02-14 | 2017-07-19 | Optinose AS | Delivery device |
| GB0602980D0 (en) | 2006-02-14 | 2006-03-29 | Optinose As | Delivery device and method |
| GB0604319D0 (en) | 2006-03-03 | 2006-04-12 | Optinose As | Nasal delivery |
| GB0604444D0 (en) | 2006-03-06 | 2006-04-12 | Optinose As | Nasal devices |
| GB0605799D0 (en) | 2006-03-23 | 2006-05-03 | Optinose As | Nasal delivery devices |
| GB2437488A (en) | 2006-04-25 | 2007-10-31 | Optinose As | Pharmaceutical oily formulation for nasal or buccal administration |
| GB2438834A (en) | 2006-06-08 | 2007-12-12 | Optinose As | Intranasal protein administration |
| GB2440316A (en) | 2006-07-25 | 2008-01-30 | Optinose As | Nasal inhaler with scrubber |
| WO2008067254A2 (en) * | 2006-11-27 | 2008-06-05 | Abbott Respiratory Llc | Nasal drug delivery device and method |
| GB0623728D0 (en) | 2006-11-28 | 2007-01-10 | Optinose As | Delivery devices |
| GB0623731D0 (en) | 2006-11-28 | 2007-01-10 | Optinose As | Delivery device |
| GB0623732D0 (en) | 2006-11-28 | 2007-01-10 | Optinose As | Powder delivery devices |
| CN200994915Y (zh) * | 2006-12-27 | 2007-12-26 | 游世规 | 一种鼻腔清洗器 |
| WO2008122018A1 (en) | 2007-04-02 | 2008-10-09 | Abbott Respiratory Llc | Breath actuated nasal pump |
| GB2448193A (en) | 2007-04-05 | 2008-10-08 | Optinose As | Nasal delivery device |
| GB2448183A (en) | 2007-04-05 | 2008-10-08 | Optinose As | Nasal powder delivery device |
| GB2471973B (en) | 2007-10-03 | 2012-03-14 | Optinose As | Nasal delivery devices |
| GB0719299D0 (en) | 2007-10-03 | 2007-11-14 | Optinose As | Nasal delivery devices |
| WO2010029441A2 (en) | 2008-09-15 | 2010-03-18 | Optinose As | Nasal delivery |
| ES2728423T3 (es) * | 2009-01-27 | 2019-10-24 | De La Mer Laboratoire | Cánula para la administración de una solución fluida en una ventana de la nariz |
| EP2575941B1 (en) * | 2010-06-04 | 2018-03-28 | The Goverment Of The United States Of America As Represented By The Secretary Of Health And Human Services, Centers For Disease Control And | Nasal aerosol delivery system |
| GB201015371D0 (en) | 2010-09-14 | 2010-10-27 | Optinose As | Nasal delivery |
| US9949923B2 (en) | 2011-03-15 | 2018-04-24 | Optinose As | Nasal delivery |
| CA2865353C (en) | 2012-02-24 | 2021-07-13 | Optinose As | Nasal delivery devices |
| IN2014DN07610A (cg-RX-API-DMAC7.html) | 2012-02-24 | 2015-05-15 | Optinose As | |
| EP3281664B2 (en) | 2012-02-24 | 2025-10-22 | Optinose, Inc. | Nasal delivery devices |
| BR112015024869A8 (pt) | 2013-03-26 | 2019-12-17 | Optinose As | uso de um agente terapêutico e/ou de diôxido de carbono para tratar um paciente e aparelhos e métodos para tratar terapeuticamente um paciente |
| US11554229B2 (en) | 2013-03-26 | 2023-01-17 | OptiNose Inc. | Nasal administration |
| USD725769S1 (en) | 2013-05-23 | 2015-03-31 | Optinose As | Nasal delivery device |
| USD723156S1 (en) | 2013-05-23 | 2015-02-24 | Optinose As | Nasal delivery device |
-
2013
- 2013-02-25 IN IN7610DEN2014 patent/IN2014DN07610A/en unknown
- 2013-02-25 ES ES13711301.5T patent/ES2683865T3/es active Active
- 2013-02-25 RU RU2014138492A patent/RU2644293C2/ru active
- 2013-02-25 MX MX2014010146A patent/MX358062B/es active IP Right Grant
- 2013-02-25 US US14/380,836 patent/US10179216B2/en active Active
- 2013-02-25 WO PCT/EP2013/053748 patent/WO2013124493A1/en not_active Ceased
- 2013-02-25 CN CN201380021179.2A patent/CN104428024B/zh active Active
- 2013-02-25 EP EP13711301.5A patent/EP2817053B1/en active Active
- 2013-02-25 PL PL13711301T patent/PL2817053T3/pl unknown
- 2013-02-25 CA CA2865355A patent/CA2865355C/en active Active
- 2013-02-25 DK DK13711301.5T patent/DK2817053T3/en active
- 2013-02-25 JP JP2014558147A patent/JP6382723B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2865355C (en) | 2021-02-16 |
| RU2014138492A (ru) | 2016-04-10 |
| JP2015507991A (ja) | 2015-03-16 |
| CN104428024B (zh) | 2018-06-01 |
| US10179216B2 (en) | 2019-01-15 |
| WO2013124493A1 (en) | 2013-08-29 |
| RU2644293C2 (ru) | 2018-02-08 |
| IN2014DN07610A (cg-RX-API-DMAC7.html) | 2015-05-15 |
| ES2683865T3 (es) | 2018-09-28 |
| US20150246194A1 (en) | 2015-09-03 |
| EP2817053B1 (en) | 2018-05-30 |
| JP6382723B2 (ja) | 2018-08-29 |
| PL2817053T3 (pl) | 2019-01-31 |
| MX358062B (es) | 2018-08-03 |
| CN104428024A (zh) | 2015-03-18 |
| MX2014010146A (es) | 2015-10-22 |
| EP2817053A1 (en) | 2014-12-31 |
| HK1207010A1 (en) | 2016-01-22 |
| CA2865355A1 (en) | 2013-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2817053T3 (en) | NATIONAL SUBMISSION DEVICES | |
| US20250235642A1 (en) | Nasal delivery devices | |
| US20210290867A1 (en) | Nasal delivery devices | |
| EP1988953B1 (en) | Delivery device | |
| HK1207010B (en) | Nasal delivery devices | |
| HK1205699B (en) | Nasal delivery devices | |
| HK1207994B (en) | Nasal delivery devices |